Exenatide biobetter - Biolingus

Drug Profile

Exenatide biobetter - Biolingus

Alternative Names: Exenatide oral - Biolingus; Exenatide sublingual - Biolingus; Project A1 (OPUS) - Biolingus

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vitapharm Technology Development
  • Developer Biolingus; Vitapharm Technology Development
  • Class Antihyperglycaemics; Biobetters; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 18 Sep 2017 Exanatide biobetter - Biolingus is available for licensing as of 18 Sep 2017. http://www.biolingus.ch/index.html#partners
  • 18 Sep 2017 Discontinued - Phase-I for Type-2 diabetes mellitus in China (Sublingual) before September 2017 (Biolingus pipeline, September 2017)
  • 18 Sep 2017 Preclinical trials in Type-2 diabetes mellitus in Switzerland (Sublingual) before September 2017 (Biolingus pipeline, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top